Charles River Laboratories Intl. (NYSE:CRL) received a $116.00 price target from Royal Bank of Canada in a research note issued on Tuesday. The firm currently has a “hold” rating on the medical research company’s stock. Royal Bank of Canada’s price objective would indicate a potential upside of 5.16% from the stock’s previous close.

Other equities analysts also recently issued reports about the company. SunTrust Banks upgraded Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and lifted their price target for the stock from $107.66 to $125.00 in a research note on Wednesday. Robert W. Baird set a $123.00 price target on Charles River Laboratories Intl. and gave the stock a “buy” rating in a research note on Tuesday. Bank of America decreased their price target on Charles River Laboratories Intl. from $117.00 to $115.00 and set a “buy” rating for the company in a research note on Friday, November 10th. Zacks Investment Research upgraded Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and set a $129.00 price target for the company in a research note on Tuesday, October 24th. Finally, Argus started coverage on Charles River Laboratories Intl. in a research note on Wednesday, December 13th. They issued a “buy” rating and a $120.00 price target for the company. Seven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Charles River Laboratories Intl. currently has an average rating of “Buy” and a consensus target price of $115.15.

Shares of Charles River Laboratories Intl. (CRL) opened at $110.31 on Tuesday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.62 and a current ratio of 1.88. The firm has a market capitalization of $4,830.40, a PE ratio of 26.93, a PEG ratio of 1.50 and a beta of 0.74. Charles River Laboratories Intl. has a 52 week low of $86.25 and a 52 week high of $119.05.

Charles River Laboratories Intl. (NYSE:CRL) last announced its earnings results on Tuesday, February 13th. The medical research company reported $1.40 earnings per share for the quarter, beating the consensus estimate of $1.26 by $0.14. The company had revenue of $478.50 million during the quarter, compared to the consensus estimate of $475.02 million. Charles River Laboratories Intl. had a return on equity of 26.58% and a net margin of 10.72%. The company’s revenue was up 2.5% on a year-over-year basis. During the same period last year, the firm earned $1.21 earnings per share. sell-side analysts predict that Charles River Laboratories Intl. will post 5.14 EPS for the current fiscal year.

In other Charles River Laboratories Intl. news, Director Online Communications Bdirect sold 131,000 shares of the firm’s stock in a transaction dated Thursday, January 18th. The shares were sold at an average price of $0.29, for a total value of $37,990.00. Also, Director Robert J. Bertolini sold 3,609 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $110.22, for a total transaction of $397,783.98. The disclosure for this sale can be found here. Insiders sold 195,673 shares of company stock valued at $2,644,046 over the last quarter. Insiders own 2.20% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of CRL. Tower Research Capital LLC TRC lifted its holdings in Charles River Laboratories Intl. by 1,071.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,054 shares of the medical research company’s stock worth $115,000 after acquiring an additional 964 shares during the last quarter. YorkBridge Wealth Partners LLC lifted its holdings in Charles River Laboratories Intl. by 445.5% in the third quarter. YorkBridge Wealth Partners LLC now owns 1,091 shares of the medical research company’s stock worth $118,000 after acquiring an additional 891 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. lifted its holdings in Charles River Laboratories Intl. by 69.0% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,342 shares of the medical research company’s stock worth $145,000 after acquiring an additional 548 shares during the last quarter. Advisor Group Inc. lifted its holdings in Charles River Laboratories Intl. by 159.4% in the third quarter. Advisor Group Inc. now owns 1,538 shares of the medical research company’s stock worth $165,000 after acquiring an additional 945 shares during the last quarter. Finally, Zions Bancorporation bought a new position in Charles River Laboratories Intl. in the third quarter worth about $212,000. 97.13% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This news story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.thecerbatgem.com/2018/02/15/charles-river-laboratories-intl-crl-pt-set-at-116-00-by-royal-bank-of-canada.html.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Analyst Recommendations for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.